Duchenne muscular dystrophy: CRISPR/Cas9 treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Liposome-Enabled Nanomaterials for Muscle Regeneration.Small methods · 2025
   Review
2. High-Throughput Screening to Identify Novel Compounds Affecting the Genome Editing Efficiency of CRISPR System.Molecules (Basel, Switzerland) · 2025
   Article
3. Mitochondria: emerging therapeutic strategies for oocyte rescue.Reproductive sciences (Thousand Oaks, Calif.) · 2022
   Review
4. Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector viaInternational journal of molecular sciences · 2022
   Review
5. Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review.International journal of molecular sciences · 2022
   Review
6. A glance at the application of CRISPR/Cas9 gene-editing technology in cardiovascular diseases.Journal of cardiovascular and thoracic research · 2022
   Review
7. A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy.Frontiers in pharmacology · 2022
   Review
8. Dystrophin gene editing by CRISPR/Cas9 system in human skeletal muscle cell line (HSkMC).Iranian journal of basic medical sciences · 2021
   Article
9. Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy.Genes & diseases · 2021
   Review
10. Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases.International journal of molecular sciences · 2020
    Review
11. Neuromuscular diseases rehabilitation in the era of gene therapy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Article
12. A glance at genome editing with CRISPR-Cas9 technology.Current genetics · 2020
    Review
13. CRISPR/Cas9-Mediated miR-29b Editing as a Treatment of Different Types of Muscle Atrophy in Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2020
    Article
14. Heterogenetic parabiosis between healthy and dystrophic mice improve the histopathology in muscular dystrophy.Scientific reports · 2020
    Article
15. Stem Cell Aging in Skeletal Muscle Regeneration and Disease.International journal of molecular sciences · 2020
    Review
16. Orienting Muscle Stem Cells for Regeneration in Homeostasis, Aging, and Disease.Cell stem cell · 2018
    Review
17. [A review of gene therapy for Duchenne muscular dystrophy].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018
    Review
18. Current and Emerging Therapies for Duchenne Muscular Dystrophy.Current treatment options in neurology · 2018
    Review
19. Molecular Therapies for Muscular Dystrophies.Current treatment options in neurology · 2018
    Review
20. Benefits of Prenatal Taurine Supplementation in Preventing the Onset of Acute Damage in the Mdx Mouse.PLoS currents · 2017
    Article

Corrections and comments

• Comment on
  Evidence-based path to newborn screening for Duchenne muscular dystrophy.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as